Independent fund research. Built on SEC filings.

How we research funds

ETF overlap

PHLAX vs QAAGZX overlap: 51% of top holdings shared

Bottom line

How much do PHLAX and QAAGZX overlap?

51% of their top holdings overlap by weight. 9 securities appear in both funds' top 25, making up 48.2% of PHLAX's assets and 34.8% of QAAGZX's. They share a meaningful core but differ in the rest of the portfolio.

QAAGZX holds far more positions (277 vs 55), so it is broader beyond the top names.

Updated Nov 22, 2026

Overlap at a glance

PHLAXQAAGZX
Weight overlap (top 25)51%
Shared holdings9
Weight in shared holdings48.2%34.8%
Total positions55277
Expense ratio1.15%0.86%
Holdings as ofMay 29, 2026Jun 30, 2026

Source: SEC Form N-PORT (periods May 29, 2026 / Jun 30, 2026)

Holdings PHLAX and QAAGZX have in common

Holding% of PHLAX% of QAAGZXOverlap
Eli Lilly & Company LLY17.35%14.06%14.06%
Merck & Company Inc MRK6.06%4.00%4.00%
Unitedhealth Group Inc UNH5.87%5.88%5.87%
Thermo Fisher Scientific Inc TMO4.56%2.53%2.53%
Vertex Pharmaceuticals Inc VRTX3.37%2.26%2.26%
Danaher Corp DHR3.28%1.44%1.44%
Intuitive Surgical Inc ISRG3.07%1.89%1.89%
Cvs Health Corp CVS2.52%0.93%0.93%
Stryker Corp SYK2.16%1.78%1.78%

Source: SEC Form N-PORT (periods May 29, 2026 / Jun 30, 2026)

Free weekly newsletter

The Fund Letter

Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.

Free. Unsubscribe anytime. We never sell your email.

What each fund holds that the other doesn't

Top-25 holdings that appear in only one of the two funds' top 25.

Only in PHLAX

  1. Argenx Se — 3.55%
  2. Lonza Group Ag — 3.02%
  3. (PIPA070) PGIM Core Government Money Market Fund — 2.50%
  4. Insmed Inc — 2.28%
  5. Roivant Sciences Ltd — 2.21%
  6. Sionna Therapeutics Inc — 2.01%
  7. Beone Medicines Ltd — 1.82%
  8. Vaxcyte Inc — 1.77%
  9. Align Technology Inc — 1.75%
  10. Agilent Technologies Inc — 1.73%
  11. Palvella Therapeutics Inc — 1.56%
  12. Apogee Therapeutics Inc — 1.42%
  13. Cabaletta Bio Inc — 1.35%
  14. Prudential Investment Portfolios 9 — 1.31%
  15. Newamsterdam Pharma Company Nv — 1.30%

Only in QAAGZX

  1. Johnson & Johnson — 6.64%
  2. Abbvie Inc — 5.12%
  3. Gilead Sciences Inc — 2.79%
  4. Bristol-myers Squibb Co — 2.12%
  5. Abbott Laboratories — 1.91%
  6. Amgen Inc — 1.80%
  7. Elevance Health Inc — 1.54%
  8. Natera Inc — 1.44%
  9. Guardant Health Inc — 1.22%
  10. Cardinal Health Inc — 1.04%
  11. Royalty Pharma Plc- Cl A — 0.97%
  12. Tenet Healthcare Corp — 0.94%
  13. Kymera Therapeutics Inc — 0.89%
  14. T. Rowe Price Government Reserve Fund — 0.87%
  15. Protagonist Therapeutics Inc — 0.85%

Asset mix

Asset typePHLAXQAAGZX
Stocks97.8%96.9%
Cash & short-term funds3.8%0.9%
Preferred stock—2.2%
Bonds—0.1%

Source: SEC Form N-PORT (periods May 29, 2026 / Jun 30, 2026)

Country mix

CountryPHLAXQAAGZX
US84.7%92.3%
NL5.4%1.0%
CH4.8%0.5%
BM2.2%0.7%
GB1.1%1.8%
CA1.0%0.6%
IL1.0%0.2%
DE0.9%—

Source: SEC Form N-PORT (periods May 29, 2026 / Jun 30, 2026)

Check another pair

FAQ

How much do PHLAX and QAAGZX overlap?
About 51% by weight. 9 securities appear in both funds' top 25 holdings; they make up 48.2% of PHLAX's assets and 34.8% of QAAGZX's. They share a meaningful core but differ in the rest of the portfolio.
What stocks do PHLAX and QAAGZX have in common?
The largest shared holdings are Eli Lilly & Company, Unitedhealth Group Inc, Merck & Company Inc, Thermo Fisher Scientific Inc, Vertex Pharmaceuticals Inc.
Should I own both PHLAX and QAAGZX?
They overlap in part. Owning both concentrates you in the shared names; check that the combined weight in those stocks is what you intend.
Which holds more stocks, PHLAX or QAAGZX?
QAAGZX is broader, with 277 positions versus 55 for PHLAX. Overlap here is measured on each fund's top 25 holdings, which carry most of the weight.

Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.